Targeting the HGF/c-met axis: State of play

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1077-1079

  Yap, Timothy A ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AMG 102; BEVACIZUMAB; FORETINIB; MONOCLONAL ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SGX 523; UNCLASSIFIED DRUG; XL 184; XL 880;

CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; DYSPNEA; EDITORIAL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENE AMPLIFICATION; HEPATOCYTE GROWTH FACTOR; HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 77952147465     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0122     Document Type: Editorial

References (29)

1. Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010;9:400-409
2. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-2214
3. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516 (Pubitemid 351767118)
4. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
5. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18: 2343-2350
6. Lindor NM, Dechet CB, Greene MH, et al. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 2001;5:101-106
7. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043
8. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932-20937
9. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-1729
10. Kirchhofer D, Yao X, Peek M, et al. Structural and functional basis of the serine protease-like hepatocyte growth factor β-chain in Met binding and signaling. J Biol Chem 2004;279:39915-39924 (Pubitemid 39258264)
11. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J 2004;23:2325-2335 (Pubitemid 38954840)
12. Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16:699-710.
13. Jeay S, Munshi N, Hill J, et al. ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells [abstract 2369]. Proceedings of the American Association for Cancer Research Annual Meeting, Los Angeles, CA. 2007 Apr 14-18, Philadelphia: AACR; 2007.
14. Merchant M, Zheng Z, Romero M, et al. One-armed 5D5 (OA5D5) is a potent humanized HGF-blocking anti-c-Met monovalent antibody that inhibits HGF-dependent activity in vitro and demonstrates anti-tumor efficacy in vivo. American Association for Cancer Research Meeting Abstracts. 2007, LB-372.
15. Munshi N, Jeay S, Hill J, et al. ARQ 197, a highly selective small molecule inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells [abstract 2367]. Proceedings of the American Association for Cancer Research Annual Meeting, Los Angeles, CA. 2007 Apr 14-18, Philadelphia: AACR; 2007.
16. Salgia R, Peterson A, Eppler SA. Phase I, open-label, dose escalation study of the safety and pharmacology of MetMAb, A monovalent antagonist antibody to the recetor c-Met, administered IV in patients with locally advanced or metastatic solid tumors [abstract 411]. Proceedings of the 20th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Geneva, Switzerland. 2008 Oct 21-24.
17. Yap T, Frentzas S, Tunariu N, et al. Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. J Clin Oncol 2009;27:3523.
18. Mekhail T, Rich T, Rosen L, et al. Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol 2009;27:3548.
19. ClinicalTrails gov. Bethesda, MD: U S. National Institutes of Health. Available from: http://www.clinicaltrials.gov.
20. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69:8009-8016
21. Janne P, Wax M, Leach J, Engelman J. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical design. Eur J Cancer 2008;6:552.
22. Eder J, Heath E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007;25:3526.
23. Srinivasan R, Choueiri T, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2008;26:5103.
24. Salgia R, Sherman S, Hong D, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 2008;26:3522.
25. De Groot J, Prados M, Urquhart T, et al. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol 2009;27:2047.
26. Srinivasan R, Linehan W, Vaishampayan U, et al. A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/ VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2009;27:5103.
27. Jhawer M, Kindler H, Wainberg Z, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 2009;27:4502.
28. Carden CP, Sarker D, Postel-Vinay S, et al. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today 2009.
29. Kwak E, Camidge D, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27:3509.